- Home
- NUVB vs PHK Comparison
NUVB vs PHK Comparison
Compare NUVB & PHK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- PHK
- Stock Information
- Founded
- NUVB 2018
- PHK 2003
- Country
- NUVB United States
- PHK United States
- Employees
- NUVB N/A
- PHK N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- PHK Finance/Investors Services
- Sector
- NUVB Health Care
- PHK Finance
- Exchange
- NUVB Nasdaq
- PHK Nasdaq
- Market Cap
- NUVB 850.3M
- PHK 777.7M
- IPO Year
- NUVB N/A
- PHK N/A
- Fundamental
- Price
- NUVB $2.81
- PHK $4.98
- Analyst Decision
- NUVB Strong Buy
- PHK
- Analyst Count
- NUVB 6
- PHK 0
- Target Price
- NUVB $6.33
- PHK N/A
- AVG Volume (30 Days)
- NUVB 2.5M
- PHK 491.5K
- Earning Date
- NUVB 11-06-2024
- PHK 01-01-0001
- Dividend Yield
- NUVB N/A
- PHK 12.61%
- EPS Growth
- NUVB N/A
- PHK N/A
- EPS
- NUVB N/A
- PHK N/A
- Revenue
- NUVB $2,162,000.00
- PHK N/A
- Revenue This Year
- NUVB N/A
- PHK N/A
- Revenue Next Year
- NUVB N/A
- PHK N/A
- P/E Ratio
- NUVB N/A
- PHK N/A
- Revenue Growth
- NUVB N/A
- PHK N/A
- 52 Week Low
- NUVB $1.22
- PHK $4.13
- 52 Week High
- NUVB $4.16
- PHK $5.15
- Technical
- Relative Strength Index (RSI)
- NUVB 58.25
- PHK 46.05
- Support Level
- NUVB $2.44
- PHK $4.87
- Resistance Level
- NUVB $3.07
- PHK $5.00
- Average True Range (ATR)
- NUVB 0.18
- PHK 0.05
- MACD
- NUVB 0.01
- PHK -0.01
- Stochastic Oscillator
- NUVB 69.44
- PHK 47.83
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About PHK Pimco High Income Fund
PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. Its secondary objective is to seek capital appreciation.